sounded an alarm of immense proportions. The second article focuses on the psychology of perception and our inability to be objective, even with the 'gold standard' of RCT's.
The first lay article, by David H. Freedman in the November 2010 Atlantic, 'Lies, Damned Lies, and Medical Science', goes back to 2001 and summarizes questions initially raised regarding choice of patients for appendectomy (Albanian immigrants vs. patients with Greek names to increase 'scalpel time!). Then Freedman describes his interview experience with Ioannidis's team at Ioannina Medical School and their controversial agenda, Contradiction and publication bias in reported Randomized Clinical Trials (RCT's) of therapeutic interventions. He also raised the issue of whether drug firms were determining their studies in biased fashion to achieve more desirable results, i.e., the problem was asking the wrong question or asking it in a biased manner. He estimated that 80% of non-randomized studies turned out to be wrong, but more concerning that 25% of RCT's are as well! Ioannidis's first article, published in PLoS Medicine in 2005 [3] became the most-downloaded article in the publication's history. Freedman also refers to wellknown examples such as hormone replacement therapy to prevent heart disease and the plethora of vitamin publications that have proved erroneous, both in Ioannidis's view and in more recent studies [5, 6] .
The second lay article [2] , by Jonah Lehrer in the December 10, 2013 issue of the New Yorker, 'The Truth Wears Off', begins with a discussion of declining effectiveness of second-generation antipsychotics, the issue of replicability, and that many medical concepts enshrined in textbooks have proven unconfirmable or outright wrong. He then reviews the work of Jonathan Schooler, a professor at the university of CaliforniaSanta Barbara and other researchers on 'verbal Editorial 'Lies, damned lies, and statistics': pharmaceutical, device, and academic enterprises 'in the dock'* overshadowing', where 'subjects shown a face and asked to describe it were much less likely to recognize the face when shown it later than those who had simply looked at it.' The article then proceeds to discuss other psychological concepts and the difficulty in getting negative results published in journals (publication bias). He also refers to the statistical technique of constructing a funnel graph discriminating studies with larger sample size from those with smaller size to evaluated possible bias. Schooler then raises the problem of faulty study design-'We're wasting too much time chasing after bad studies and underpowered experiments. Every researcher should have to spell out, in advance, how many subjects they're going to use, and what exactly they're testing, and what constitutes a sufficient level of proof…' While the declining effect of secondgeneration antipsychotics may be 'regression to the mean', the decline may be related to 'the decline of illusion', not only in medical research of other disciplines as well. The article also cites the Work of Ioannidis referenced above and the quest for funding/ statistical significance in clinical research.
However, the news is not all hopeless, just disturbing. In addition, it reminds us of the need for asking the right research questions, exercising better attention to study design, and reporting, and exercising restraint in statistical analysis. Declining effect of drugs should not come as a surprise, as evidenced by the ongoing challenge of drug resistance in treating falciparum malaria [7, 8] and the perplexing problem of antibiotic resistance [9] .
In his PLoS paper [3] , Ioannidis expresses the opinion that 'Claimed research findings may often be simply accurate measures of the prevailing bias' and makes the following suggestions for improving the situation:
1. Better-powered evidence, such as larger studies and lower-biased meta-analyses. Such evidence should be based on a higher degree of pretest probability than is currently practiced.
2. When research is conducted by several teams, use all the data for analysis and avoid emphasizing the results from just one.
3. Instead of chasing statistical significance, consider the chances of testing a true relationship and the meaning of R-the pre-study odds-in designing experiments as shown in Table 1 . In his 2005 JAMA paper [4] , Ioannidis focused on highly-cited articles in widely-read medical journals, and further analyzed 49 highly reputed research findings of the past 13 years, based on what we now call 'impact factor'(also subject to financial conflict of interest [10] ). Forty-five claimed effective interventions, and seven (16%) were contradicted in subsequent studies, seven others (16%) reported exaggerated affects, 20 (44%) were replicated, and 11 (24%) remained unchallenged. Two of the bestknown contradicted studies are the Nurses' Health Study (subsequent studies show that estrogen increased CAD risk in post-menopausal women), and the Health Professionals Study (subsequent studies showed that vitamin E supplementation does not reduce CAD in men). He further concludes that 'even the most highly cited randomized trials may be challenged and refuted over time, especially small ones'.
A few additional suggestions and issues have surfaced since these original 2005 reports, such as addressing missing data in clinical trials [11, 12] and the need to have full access to trial protocols and all results [13] . Other authors have modeled the impact of sequential analysis on decision-making in research [14] and the use of the Delphi technique to determine which outcomes to measure in clinical trials [15] .
The question of objectivity was also recently emphasized in an article titled 'The interpretation of systematic reviews with meta-analysis: an objective or subjective process?' [16] The question they posed was on the efficacy of intravenous magnesium in the early post-myocardial infarction period. They organized the articles chronologically and separated them into packages with varying numbers of RCT reports and meta-analyses. They presented the packages to eight different reviewers, all of whom had published systematic reviews and/or metaanalyses, to answer three clinical questions: 1) Whether they believed magnesium is now proven beneficial; 2) Whether they believed magnesium will eventually be proven to be beneficial; and 3) Whether they would recommend its use at this time.
Considerable disagreement ensued as the data became more heterogeneous for each package and each question. Some reviewers became more skeptical of its value and some became less skeptical over time. The authors concluded: 'the interpretation of the results of systematic reviews and meta-analyses includes a subjective component that can lead to discordant conclusions that are independent of the methodology used to obtain or analyze the data'.
What does all this tell us? I suggest: 1. Consider carefully the pre-test probability for a given outcome of an experiment.
2. Be sure to ask the right questions, and stay focused on these questions in conducting a trial.
3. For industry-sponsored drug trials, register at the outset, fully disclose protocols, and include all participants in analyses. Be careful about over-use of data mining software. Stop the fa ade of dressing up your results [17] .
4. Always reveal fully your funding sources and potential conflicts of interest.
5. Follow the CONSORT 2010 statement regarding clinical trials reporting [18] .
6. Do a better job of graphical presentation of your results [19, 20] .
7. For large trials across multiple countries and cultures, be mindful of the cultural, ethical, and scientific implications of such trials [21] .
8. Publish negative results -editors, please note [22] .
Finally, a brief comment about fraud in medical research: it must not be tolerated! The recent exposure of the Wakefield/autism debacle [23, 24] serves as a reminder of our responsibility as physicians, researchers, and teachers to be vigilant and set a good example for those who follow. Edmund Burke's oftquoted statement serves as a blunt reminder: 'All that is necessary for the triumph of evil is for good men to do nothing'.
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